Translational Research

At Vetigenics, we are committed to supporting the advancement of both human and animal health through our antibody-discovery platform. Our expertise in comparative oncology allows us to generate reagent antibodies that can be evaluated in canine immunotherapy clinical trials to treat cancer and can also be employed in a diagnostic capacity to better understand the immunological mechanisms that might be involved in clinical responses.

We partner with veterinary clinics and research institutions, supplying antibody-based therapies for industry and investigator-initiated canine clinical trials and biomarker discovery. The ultimate goal is to bring safer, more effective therapies to our canine companions and their owners. By supporting comparative oncology and immunology research, we help to accelerate the development and understanding of novel treatments for a multitude of different disease processes and improve outcomes for patients of all species.